GeoVax Announces Issuance of Cancer Vaccine Patent
March 22 2022 - 9:00AM
via NewMediaWire --
GeoVax Labs,
Inc. (Nasdaq: GOVX), a biotechnology company developing
human immunotherapies and vaccines against infectious diseases and
cancer, today announced that the U.S. Patent and Trademark Office
has issued Patent No. 11278607 to GeoVax, pursuant to the Company’s
patent application No. 16/068,527 entitled “Compositions and
Methods for Generating an Immune Response to a Tumor Associated
Antigen.”
The claims granted by the patent generally cover
GeoVax’s vector platform for expressing tumor associated antigens
in virus-like particles (VLPs) from a Modified Vaccinia Ankara
(MVA) viral vector and encompass GeoVax’s Mucin 1 (MUC1)
tumor-associated antigen immunotherapy candidate. The Company uses
its GV-MVA-VLP™ vaccine platform to express abnormal, aberrantly
glycosylated forms of the cell surface-associated MUC1 protein that
is associated with a wide range of cancers, including breast,
colon, ovarian, prostate, pancreatic, and lung.
David Dodd, GeoVax President and CEO, commented,
“The initial results with our MVA-VLP-MUC1 immunotherapy candidates
have been encouraging and we recently began an IND-enabling animal
study with Dr. Pinku Mukherjee at the University of North Carolina
at Charlotte to define the optimal course and schedule of
vaccination to define a protocol that can be evaluated in a Phase 1
clinical trial. We believe our MVA vector platform is well-suited
for development of therapeutic cancer vaccines based on the
expression of tumor-associated antigens such as MUC1 and Cyclin B1,
among others.”
Dodd added, “In addition to our work with MUC1, we
are also developing Gedeptin®, a novel patented product for the
treatment of solid tumors currently in a Phase 1/2 trial evaluating
its safety and efficacy in patients with recurrent head and neck
squamous cell carcinoma (HNSCC). We are excited by the potential
for GeoVax’s growing immuno-oncology pipeline.”
About GeoVax
GeoVax Labs, Inc. is a clinical-stage
biotechnology company developing human vaccines and immunotherapies
against infectious diseases and cancer using novel proprietary
platforms. GeoVax’s product pipeline includes two ongoing Phase 2
clinical trials of GEO-CM04S1 (formerly COH04S1) for COVID-19 as a
universal booster vaccine to mRNA vaccines authorized by the U.S.
Food and Drug Administration (FDA) and as a primary vaccine for use
in immunocompromised patients. In addition to GEO-CM04S1 for
COVID-19, GeoVax is developing GEO-CM02 as a pan-coronavirus
vaccine. The Company is also conducting a Phase 1/2 clinical trial
of Gedeptin® for treatment of head and neck cancer. Gedeptin® has
been granted orphan drug status by the FDA. Additional research and
development programs include preventive vaccines against Zika
Virus, hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa)
and malaria, as well as immunotherapies for multiple solid tumors.
The Company’s portfolio of wholly owned, co-owned, and in-licensed
intellectual property stands at over 70 granted or pending patent
applications spread over 20 patent families.
For additional information about GeoVax, visit our
website: www.geovax.com.
Forward-Looking Statements
This release contains forward-looking statements
regarding GeoVax’s business plans. The words “believe,” “look
forward to,” “may,” “estimate,” “continue,” “anticipate,” “intend,”
“should,” “plan,” “could,” “target,” “potential,” “is likely,”
“will,” “expect” and similar expressions, as they relate to us, are
intended to identify forward-looking statements. We have based
these forward-looking statements largely on our current
expectations and projections about future events and financial
trends that we believe may affect our financial condition, results
of operations, business strategy and financial needs. Actual
results may differ materially from those included in these
statements due to a variety of factors, including whether: GeoVax
is able to obtain acceptable results from ongoing or future
clinical trials of its investigational products, GeoVax’s
immuno-oncology products and preventative vaccines can provoke the
desired responses, and those products or vaccines can be used
effectively, GeoVax’s viral vector technology adequately amplifies
immune responses to cancer antigens, GeoVax can develop and
manufacture its immuno-oncology products and preventative vaccines
with the desired characteristics in a timely manner, GeoVax’s
immuno-oncology products and preventative vaccines will be safe for
human use, GeoVax’s vaccines will effectively prevent targeted
infections in humans, GeoVax’s immuno-oncology products and
preventative vaccines will receive regulatory approvals necessary
to be licensed and marketed, GeoVax raises required capital to
complete development, there is development of competitive products
that may be more effective or easier to use than GeoVax’s products,
GeoVax will be able to enter into favorable manufacturing and
distribution agreements, and other factors, over which GeoVax has
no control.
Further information on our risk factors is
contained in our registration statement on Form S-3 and the
periodic reports on Form 10-Q and Form 10-K that we have filed and
will file with the SEC. Any forward-looking statement made by us
herein speaks only as of the date on which it is made. Factors or
events that could cause our actual results to differ may emerge
from time to time, and it is not possible for us to predict all of
them. We undertake no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future developments or otherwise, except as may be required by
law.
GeoVax Labs,
Inc.678-384-7220investor@geovax.com
GeoVax Labs (NASDAQ:GOVXW)
Historical Stock Chart
From Jul 2024 to Aug 2024
GeoVax Labs (NASDAQ:GOVXW)
Historical Stock Chart
From Aug 2023 to Aug 2024